ArticleClinical, cosmetic and investigational dermatology2025
Abrocitinib for Head and Neck Dermatitis: Case Series and Literature Review.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Janus kinase inhibitors enhance the efficacy of dupilumab in refractory atopic dermatitis.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Article
- Optimizing Abrocitinib Use for Atopic Dermatitis in India: Expert Recommendations for Patient Selection, Dosing, and Long‑Term Remission.Clinical, cosmetic and investigational dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Head and neck dermatitis (HND) is a recalcitrant subtype of atopic dermatitis (AD). Despite conventional therapies, including topical corticosteroids, calcineurin inhibitors, and biologics such as dupilumab, many patients remain refractory to treatment. Janus kinase (JAK) inhibitors, such as abrocitinib, offer a novel therapeutic approach targeting multiple inflammatory pathways implicated in HND. Purpose: To evaluate the efficacy of abrocitinib in refractory HND and compare its effectiveness with other JAK inhibitors (upadacitinib, baricitinib). Patients and Methods: We retrospectively analyzed three patients with HND treated with abrocitinib (100-200 mg/day). Treatment response was assessed using Eczema Area and Severity Index (EASI) scores and the Investigator's Global Assessment (IGA) of the head and neck. A PubMed literature review was conducted to compare abrocitinib with other JAK inhibitors in HND. Results: All three abrocitinib-treated patients achieved rapid skin lesion relief within 1-2 weeks and near-complete lesion clearance by Week 8. These results are consistent with clinical trial data highlighting the strong early efficacy of JAK inhibitors for head and neck lesions. While abrocitinib and upadacitinib demonstrated robust clinical responses, baricitinib showed comparatively weaker efficacy in the head and neck. Conclusion: JAK inhibitors, particularly abrocitinib and upadacitinib, may be considered as first-line therapies for refractory HND. They offer both rapid symptom relief and sustained efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.